These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 33140259)

  • 41. Developing outcomes assessments for collaborative, cross-institutional benchmarking: progress of the Australian Medical Assessment Collaboration.
    Edwards D; Wilkinson D; Canny BJ; Pearce J; Coates H
    Med Teach; 2014 Feb; 36(2):139-47. PubMed ID: 24171466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alternate financial incentives in multi-tiered formulary systems to improve accountability for outcomes.
    Chung RS; Taira DA; Noh C
    J Manag Care Pharm; 2003; 9(4):360-5. PubMed ID: 14613455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations.
    Dombernowsky T; Haedersdal M; Lassen U; Thomsen SF
    Trials; 2019 Dec; 20(1):708. PubMed ID: 31829234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementing CER: what will it take?
    Biskupiak JE; Dunn JD; Holtorf AP
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S19-29. PubMed ID: 22663296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The changing timetable for the evaluation of new products for formulary consideration.
    Giaquinta D
    Manag Care Interface; 2003 Feb; 16(2):24-5, 28. PubMed ID: 12647522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Online consumer surveys as a methodology for assessing the quality of the United States health care system.
    Bethell C; Fiorillo J; Lansky D; Hendryx M; Knickman J
    J Med Internet Res; 2004 Jan; 6(1):e2. PubMed ID: 15111268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AMCP Partnership Forum: Optimizing Prior Authorization for Appropriate Medication Selection.
    J Manag Care Spec Pharm; 2020 Jan; 26(1):55-62. PubMed ID: 31880226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Industry-Wide Survey of Academic Anesthesiology Departments Provides Up-to-Date Benchmarking Data on Surgical Anesthesia Productivity.
    Abouleish AE; Hudson ME; Levy RS; Whitten CW
    Anesth Analg; 2020 Sep; 131(3):885-892. PubMed ID: 32541253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The New South Wales Medical Record Department Benchmarking Project: a work in progress.
    Bramley M
    Health Inf Manag; 2002; 30(1):1-19. PubMed ID: 19468133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes research: collaboration among academic researchers, managed care organizations, and pharmaceutical manufacturers.
    Kong SX; Wertheimer AI
    Am J Manag Care; 1998 Jan; 4(1):28-34. PubMed ID: 10179904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A hitchhiker's guide to competitive managed care.
    Finkler M
    Manag Care Q; 1999; 7(4):25-33. PubMed ID: 10661941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. US Medical Information Websites Benchmarking: How Is the Industry Fairing in Usability?
    Paquette-Lemieux E; Hays S; Gaspo R
    Ther Innov Regul Sci; 2019 May; 53(3):340-348. PubMed ID: 29976102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Public requests for cancer cluster investigations: a survey of state health departments.
    Trumbo CW
    Am J Public Health; 2000 Aug; 90(8):1300-2. PubMed ID: 10937014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives.
    Krendyukov A; Nasy D
    Pharmaceut Med; 2020 Aug; 34(4):247-256. PubMed ID: 32557342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality assessments for cancer centers in the European Union.
    Wind A; Rajan A; van Harten WH
    BMC Health Serv Res; 2016 Sep; 16(1):474. PubMed ID: 27605036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
    Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE
    J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.